New drug cocktail shows promise for rare stomach cancer
NCT ID NCT06992362
First seen Sep 30, 2025 · Last updated May 08, 2026 · Updated 22 times
Summary
This study tests a combination of three drugs (RC48, chemotherapy, and an immunotherapy) given before and after surgery for a rare stomach cancer called hepatoid adenocarcinoma. The goal is to see if this approach can completely eliminate the tumor before surgery and prevent it from coming back. About 30 adults with HER2-positive, locally advanced disease will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOID ADENOCARCINOMA OF STOMACH are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital & Institute
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.